Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary
field that is garnering a lot of interest and investigation. Nanomedicine shows great potential …
field that is garnering a lot of interest and investigation. Nanomedicine shows great potential …
Immunotherapy: a promising approach for glioma treatment
F Yasinjan, Y **ng, H Geng, R Guo, L Yang… - Frontiers in …, 2023 - frontiersin.org
Gliomas are the most prevalent primary malignant brain tumors worldwide, with
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …
Immunotherapy for glioblastoma: Current state, challenges, and future perspectives
Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …
Receptor ligand-free mesoporous silica nanoparticles: a streamlined strategy for targeted drug delivery across the blood–brain barrier
Mesoporous silica nanoparticles (MSNs) represent a promising avenue for targeted brain
tumor therapy. However, the blood–brain barrier (BBB) often presents a formidable obstacle …
tumor therapy. However, the blood–brain barrier (BBB) often presents a formidable obstacle …
[HTML][HTML] Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and …
C Zhao, X Zhu, J Tan, C Mei, X Cai, F Kong - Biomedicine & …, 2024 - Elsevier
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor,
characterized by high heterogeneity, strong invasiveness, poor prognosis, and a low …
characterized by high heterogeneity, strong invasiveness, poor prognosis, and a low …
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
The adaptability of glioblastoma (GBM) cells, encouraged by complex interactions with the
tumour microenvironment (TME), currently renders GBM an incurable cancer. Despite …
tumour microenvironment (TME), currently renders GBM an incurable cancer. Despite …
Histone H3K9 Lactylation confers Temozolomide resistance in glioblastoma via LUC7L2‐mediated MLH1 intron retention
Q Yue, Z Wang, Y Shen, Y Lan, X Zhong… - Advanced …, 2024 - Wiley Online Library
Temozolomide (TMZ) resistance remains the major obstacle in the treatment of glioblastoma
(GBM). Lactylation is a novel post‐translational modification that is involved in various …
(GBM). Lactylation is a novel post‐translational modification that is involved in various …
Glioblastoma: an update in pathology, molecular mechanisms and biomarkers
Z Lan, X Li, X Zhang - International journal of molecular sciences, 2024 - mdpi.com
Glioblastoma multiforme (GBM) is the most common and malignant type of primary brain
tumor in adults. Despite important advances in understanding the molecular pathogenesis …
tumor in adults. Despite important advances in understanding the molecular pathogenesis …